Merzel Šabović Eva Klara, Kraner Šumenjak Tadeja, Božič Mijovski Mojca, Janić Miodrag
Department of Dermatovenerology, University Medical Centre Ljubljana, Gradiškova ulica 10, Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, Vrazov trg 2, Ljubljana, Slovenia.
Immunol Res. 2025 Jan 8;73(1):28. doi: 10.1007/s12026-024-09584-4.
Psoriasis is a chronic, immune-mediated disease. The systemic inflammation triggered by psoriasis contributes significantly to increased cardiovascular risk. While various treatments completely clear the skin, the associated effects on systemic inflammation are not yet clear. We investigated residual systemic inflammation in successfully treated patients. Circulating disease-specific and non-specific inflammatory markers were measured and compared in 80 psoriasis patients (aged 30-45 years) successfully treated with topical therapy, methotrexate, adalimumab, secukinumab or guselkumab, and in 20 healthy controls. Non-specific inflammatory markers (high-sensitivity C-reactive protein (hs-CRP), complete blood count (CBC) parameters, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), mean platelet volume-to-platelet ratio (MPR), and red blood cell distribution width-to-platelet ratio (RPR)) and disease-specific inflammatory markers (interferon-γ (IFN-γ), tumor necrosis factor (TNF), interleukin (IL)-1β, IL-12p70, IL-17, and IL-23) were measured and compared between groups. Disease-specific cytokines (IFN-γ, TNF, IL-1β, IL-12p70, and IL-17, but not IL-23), were significantly elevated in patients compared to controls, while non-specific inflammatory markers showed no differences compared to controls. The residual disease-specific cytokines were similarly elevated in all five treated groups. In addition, they correlated significantly with body mass index (BMI) and waist circumference. Our results suggest that psoriasis patients have elevated residual disease-specific cytokines despite successful treatment, while the non-specific inflammatory markers are similar to those in control subjects. Residual disease-specific inflammatory markers correlated with BMI and waist circumference. A possible beneficial effect of body weight control in psoriasis patients merits further investigation. The study was registered at http://clinicaltrials.gov (identifier: NCT05957120) on July 24, 2023.
银屑病是一种慢性免疫介导性疾病。银屑病引发的全身炎症会显著增加心血管疾病风险。虽然各种治疗方法能使皮肤完全清除病变，但对全身炎症的相关影响尚不清楚。我们对成功接受治疗的患者的残余全身炎症进行了研究。对80例年龄在30至45岁之间、分别成功接受局部治疗、甲氨蝶呤、阿达木单抗、司库奇尤单抗或古塞库单抗治疗的银屑病患者以及20名健康对照者，测量并比较了循环中的疾病特异性和非特异性炎症标志物。测量并比较了两组之间的非特异性炎症标志物（高敏C反应蛋白（hs-CRP）、全血细胞计数（CBC）参数、中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）、平均血小板体积与血小板比值（MPR）以及红细胞分布宽度与血小板比值（RPR））和疾病特异性炎症标志物（干扰素-γ（IFN-γ）、肿瘤坏死因子（TNF）、白细胞介素（IL）-1β、IL-12p70、IL-17和IL-23）。与对照组相比，患者体内的疾病特异性细胞因子（IFN-γ、TNF、IL-1β、IL-12p70和IL-17，但不包括IL-23）显著升高，而非特异性炎症标志物与对照组相比无差异。在所有五个治疗组中，残余的疾病特异性细胞因子同样升高。此外，它们与体重指数（BMI）和腰围显著相关。我们的结果表明，尽管治疗成功，但银屑病患者体内的残余疾病特异性细胞因子仍升高，而非特异性炎症标志物与对照受试者相似。残余的疾病特异性炎症标志物与BMI和腰围相关。控制体重对银屑病患者可能具有的有益作用值得进一步研究。该研究于2023年7月24日在http://clinicaltrials.gov（标识符：NCT05957120）注册。
